Abstract
Aim: Immunotherapy with interferon‐alfa (IFN‐alfa) is used in a variety of diseases in‐ and outside clinical trials (e.g. chronic hepatitis, melanoma, chronic myelogenous leukemia, renal cell carcinoma, multiple myeloma). Treatment with IFN‐alfa can cause (severe) neuropsychiatric side effects. The purpose of this article is to give an updated review of data on the incidence, manifestations and prediction of psychiatric side effects of immunotherapy with IFN‐alfa. Furthermore, the article gives an overview of the management strategies and of the various theories on the pathophysiology of behavioural effects induced by cytokines.Methods: Use was made of computerized searches and of checking cross‐references of articles and book chapters. The data on the incidence, manifestations and prediction are arranged by source of information, by target symptoms and by method of ascertainment.Results: Different sources of information exist, e.g. adverse event reports of clinical trials, case descriptions and research specifically targeted on neuropsychiatric side effects. IFN‐alfa is capable of inducing depressive symptoms and syndromes; the evidence for the induction of other psychiatric side effects is weaker. The depressive syndromes induced by IFN‐alfa are in need of a more precise characterization. The results of studies on prediction of side effects are contradictory. Guidelines on managing psychiatric side effects predominantly arise from practical experience and common sense. Patient education plays a pivotal role. At this moment, there is no comprehensive theory on the pathophysiology of cytokine‐induced psychiatric side effects.Conclusion: There is sufficient empirical support for a causal relation between IFN‐alfa and the development of depressive symptoms and syndromes. Practical management of neuropsychiatric side effects begins before the start of therapy and should consist of repeated patient education, drug treatment and supportive measures. There are diverging theories on the pathophysiological backgrounds.
Similar content being viewed by others
References
Fauci AS, Braunwald E, Isselbacker KJ, Wilson JD, Martin JB, Kasper DL et al., editors. Harrisons' principles of internal medicine, 14th ed. New York: McGraw-Hill, 1998.
Vial T, Descotes J. Clinical toxicity of interferons. Drug Saf 1994; 10(2): 115–50.
Dusheiko G. Side effects of alpha interferon in hepatitis C. Hepatology 1997; 26(3 Suppl 1): 112S–21S.
Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157(6): 867–76.
Kirkwood JM, Resnick GD, Cole BF. Efficacy, safety and riskbenefit analysis of adjuvant interferon alfa-2b adjuvant therapy in melanoma. Semin Oncol 1997; 24(1 Suppl 4): 16–23.
Donnelly S. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. Oncol Nurs Forum 1998; 25(5): 921–7.
Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J-L, Maloisel F et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337(4): 223–9.
Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321(22): 1501–6.
Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B et al. Randomised trial of interferon alfa-2a as adjuvant therapy in resected primary melanoma thicker than 1,5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905–10.
McHutchinson JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavarin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339(21): 1485–92.
Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. Interferon alfa-2b alone or in combination with ribavarin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339(21): 1493–9.
Gaudin J-L, Faure P, Godinot H, Gerard F, Trepo C. The french experience of treatment of chronic type D hepatitis with a 12-months of interferon alpha-2B. Results of a randomized controlled trial. Liver 1995; 15(1): 45–52.
Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21(2): 241–3.
Fattovich G, Giustina G, Favaroto S, Ruol A, the Investigators of the Italian Liver Association. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24(1): 38–47.
Weiss K. Safety profile of interferon-alpha therapy. Semin Oncol 1998; 25(1)(Suppl I): 9–13.
Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54(5): 565–72.
Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988; 6(4): 355–9.
Rifflet H, Vuillemin E, Oberti F et al. Pulsions suicidaires chez des malades atteints d'hépatite chronique C au cours ou au décours du traitement par l'interféron alpha. Gastroenterol Clin Biol 1998; 22(3): 353–7.
Van Gool AR, Kruit WHJ, Cornelissen JJ, Berk L, Eggermont AMM, Bannink M. Management of psychiatric adverse events with immunotherapy with interferon-alfa. Acta Neuropsychiatr 1999; 11(4): 120–4.
Greenberg DB, Jonasch E, Gadd MA et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89(2): 356–62.
Lemonnier E, Condat B, Paillère-Martinot ML, Chollet R, Allilaire JF. Syndrome de persécution sous interféron: à propos d'un cas. Société Médico-Psychologique 1996; 154(4): 246–9.
Nozaki O, Takagi C, Takaoka K, Takata K, Yoshida M. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. Psychiatry Clin Neurosci 1997; 51(4): 175–80.
Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252(7): 938–41.
Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45(5): 947–50.
Mapou RL, Law WA, Wagner K, Malone JL, Skillman DR. Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodefiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci 1996; 8(1): 74–81.
Capuron L, Ravaud A, Dantzer R. Timing and specifity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients. Psychosom Med 2001; 63(3): 376–86.
Renault PF, Hoofnagle JH, Park Y, Mullen KD, Jones D, Rustgi V et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147(9): 1577–80.
Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990; 26(5): 596–600.
Hensley ML, Peterson BR, Silver RT, Larson RA, Schiffer CA, Szatrowski TP. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000; 18(6): 1301–8.
McDonald, EM, Mann, AH, Thomas, HC. Interferons as mediators of psychiatric morbidity. Lancet 1987;11(Nov 21): 1175–8.
Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alfa treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42(12): 2482–6.
Malaguernera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon-alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon-alpha. Neuropsychobiology 1998; 37(2): 93–7.
Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M et al. Neurotoxicity of interferon-alfa in melanoma therapy. Cancer 1998; 83(3): 482–9.
Scalori A, Apale P, Panizzuti F, Mascoli N, Pioltelli P, Pozzi M, et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000; 12(5): 505–9.
Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000; 15(3): 300–3.
Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha tretament for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001; 96(1): 157–64.
Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon-alfa can be used succesfully in patients with hepatitis C virus positive hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995; 7(2): 165–8.
Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patients initial affective state. N Engl J Med 1999; 340(17): 1370.
Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M et al. Immunotherapy interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105(1–2): 45–55.
Miyoaka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156(7): 1120.
Pariante CM, OrrÙ MG, Baita M, et al. Treatment with interferon-alfa in patients with chronic hepatitis and mood and anxiety disorders. Lancet 1999; 354(July 10): 131–2.
Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon-alfa. N Engl J Med 2001; 344(13): 961–6.
Kraus MR, Schäfer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon-alfa. N Engl J Med 2001; 345(5): 375–6.
Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26(5): 643–52.
Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety 1998; 7(4): 188–93.
Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18(11): 2316–26.
Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa and depression. Hepatology 2000; 31(6): 1207–11.
Gleason OC, Yates WR. Five cases of interferon-alphainduced depression treated with antidepressant therapy. Psychosomatics 1999; 40(): 510–2.
Valentine AD, Meyers CA, Talpaz M. Treatment of neurotxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995; 13(6): 561–6.
Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9(4): 273–7.
Konsman JP. Immune-to-brain communication. Academical thesis, University of Groningen, 2000.
Dantzer R, Aubert A, Bluthé R-M, Gheusi G, Cremona S, Layé S et al. Mechanisms of the behavioral effects of cytokines. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokines, stress and depression. New York: Kluwer Academic / Plenum Publishers 1999.
Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. Psychol Med 2000; 30(2): 259–68.
Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22(1): 86–90.
Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7(5): 468–73.
Maes M, Smith R, Scharpé. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995; 20(2); 111–6.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Gool, A., Kruit, W., Stoter, G. et al. Neuropsychiatric side effects of interferon‐alfa therapy. Pharm World Sci 25, 11–20 (2003). https://doi.org/10.1023/A:1022449613907
Issue Date:
DOI: https://doi.org/10.1023/A:1022449613907